ArticleLa Radiologia medica2026
Safety and efficacy of Glubran-2® endovascular embolization in acute bleeding patients with coagulopathies: a multicenter experience.
Article in La Radiologia medica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aims to analyze safety and effectiveness of glue (Glubran-2) embolization in acute bleeding patients with coagulopathies; data were analyzed according to two bleeding risk categories based on coagulation status. MATERIALS AND
methodsThis retrospective study included patients treated with glue endovascular embolization for acute bleedings in high-volume centers experienced with liquid embolics. Coagulopathy was defined as almost one of the following elements: international normalized ratio (INR) > 1.5; platelet count < 80.000/mm3; and anticoagulant and/or antiplatelet therapies at the time of embolization. If multiple conditions overlapped, patients were classified as high-risk category; otherwise, they were considered as standard risk.
resultsSixty-seven subjects were considered for this analysis. The underlying causes of bleeding were traumatic in 67.2% and spontaneous in 32.8%. At hospital admission, most patients were hemodynamically stable (86.6%). All patients took anticoagulant or antiplatelet therapies at the time of the intervention; 11.9% presented with INR > 1.5 and 14.9% had platelet counts < 80.000/mm3; 58.2% were classified as standard risk and 41.8% as high risk. Technical success was achieved in all cases while clinical success was obtained in 85%. In-hospital mortality was 6.0%. Procedure-related complications occurred in 4.5%. Comparing patients at high risk with those at standard risk, technical and clinical success rates were similar.
conclusionsIn this study Glubran-2 appeared to be an effective embolic glue in bleeding patients with coagulopathy, even in those subjects with multiple coagulopathic conditions increasing the risk of bleeding; future studies, including more patients and less trained operators, are required to confirm these outcomes.
Indexed as
Identifiers
42201644What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.